[53] The latter refers to the inhibition effect of SGLT2 inhibitors on sodium-hydrogen exchanger (NHE) activity on cardiomyocytes, which interrupts the increase in intracellular Ca2+ concentration and reduces the risk of AF. The gene discussed is SLC9C1; the disease is atrial fibrillation.